Cargando…

Thrombocytopenia Due to Direct Oral Anticoagulation and Low-Molecular-Weight Heparin

Direct oral anticoagulants (DOACs) are becoming increasingly prevalent in the general population for anticoagulation. However, rare adverse effects from these medications are still being discovered. Thrombocytopenia has previously been reported with these medications, but its clinical significance i...

Descripción completa

Detalles Bibliográficos
Autores principales: Tucker, Madeline, Padarti, Akhil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592300/
https://www.ncbi.nlm.nih.gov/pubmed/34804643
http://dx.doi.org/10.7759/cureus.18757
_version_ 1784599427578593280
author Tucker, Madeline
Padarti, Akhil
author_facet Tucker, Madeline
Padarti, Akhil
author_sort Tucker, Madeline
collection PubMed
description Direct oral anticoagulants (DOACs) are becoming increasingly prevalent in the general population for anticoagulation. However, rare adverse effects from these medications are still being discovered. Thrombocytopenia has previously been reported with these medications, but its clinical significance is still unknown. We present a patient who developed thrombocytopenia from apixaban and who subsequently developed a severe presentation of heparin-induced thrombocytopenia (HIT) from enoxaparin. This raises the possibility that thrombocytopenia from oral anticoagulants increases the likelihood of the development of heparin-induced thrombocytopenia.
format Online
Article
Text
id pubmed-8592300
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-85923002021-11-18 Thrombocytopenia Due to Direct Oral Anticoagulation and Low-Molecular-Weight Heparin Tucker, Madeline Padarti, Akhil Cureus Internal Medicine Direct oral anticoagulants (DOACs) are becoming increasingly prevalent in the general population for anticoagulation. However, rare adverse effects from these medications are still being discovered. Thrombocytopenia has previously been reported with these medications, but its clinical significance is still unknown. We present a patient who developed thrombocytopenia from apixaban and who subsequently developed a severe presentation of heparin-induced thrombocytopenia (HIT) from enoxaparin. This raises the possibility that thrombocytopenia from oral anticoagulants increases the likelihood of the development of heparin-induced thrombocytopenia. Cureus 2021-10-13 /pmc/articles/PMC8592300/ /pubmed/34804643 http://dx.doi.org/10.7759/cureus.18757 Text en Copyright © 2021, Tucker et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Tucker, Madeline
Padarti, Akhil
Thrombocytopenia Due to Direct Oral Anticoagulation and Low-Molecular-Weight Heparin
title Thrombocytopenia Due to Direct Oral Anticoagulation and Low-Molecular-Weight Heparin
title_full Thrombocytopenia Due to Direct Oral Anticoagulation and Low-Molecular-Weight Heparin
title_fullStr Thrombocytopenia Due to Direct Oral Anticoagulation and Low-Molecular-Weight Heparin
title_full_unstemmed Thrombocytopenia Due to Direct Oral Anticoagulation and Low-Molecular-Weight Heparin
title_short Thrombocytopenia Due to Direct Oral Anticoagulation and Low-Molecular-Weight Heparin
title_sort thrombocytopenia due to direct oral anticoagulation and low-molecular-weight heparin
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592300/
https://www.ncbi.nlm.nih.gov/pubmed/34804643
http://dx.doi.org/10.7759/cureus.18757
work_keys_str_mv AT tuckermadeline thrombocytopeniaduetodirectoralanticoagulationandlowmolecularweightheparin
AT padartiakhil thrombocytopeniaduetodirectoralanticoagulationandlowmolecularweightheparin